Reduced-Frequency Follow-up of Patients With Melanoma Effective and Accepted

Source: OncologyNurseAdvisor, July 2020

A reduced follow-up strategy after treatment for American Joint Committee on Cancer (AJCC) stages IB to IIC melanoma was safe and patient acceptance was high. These findings from an international phase 3 randomized trial were published in the Annals of Surgical Oncology.

A total of 207 patients were enrolled in the United Kingdom to receive either conventional (103 patients) or experimental (104 patients) follow-up schedules. The experimental group received nurse-led reduced-frequency care. Quality of life was measured at baseline, at 1 year, and at 3 years.

Only 82.1% of participants completed questionnaires through year 3. No significant difference between standard and experimental groups was reported. Nearly all study participants (93%) reported being satisfied with their care, regardless of treatment group.